Aet­na is go­ing af­ter an­oth­er phar­ma­ceu­ti­cal com­pa­ny for al­leged price fix­ing. The health in­sur­ance provider ...

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said ...

Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...

This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech ...

Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Avenzo Therapeutics pays $50M upfront to DualityBio for rights to bispecific antibody-drug conjugate DB-1418. Deal follows ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target.

XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...